- Home
- BID vs ALXO Comparison
BID vs ALXO Comparison
Compare BID & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BID | ALXO |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.8M | 172.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BID | ALXO |
|---|---|---|
| Price | $9.92 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 19.6K | ★ 1.5M |
| Earning Date | N/A | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.83 | $0.86 |
| 52 Week High | $10.02 | $2.66 |
Technical Indicators
Market Signals| Indicator | BID | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 47.68 |
| Support Level | $9.83 | $0.86 |
| Resistance Level | $10.02 | $1.30 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 50.00 | 75.97 |
Price Performance
Historical ComparisonAbout BID Tribeca Strategic Acquisition Corp. Class A Ordinary Shares
Tribeca Strategic Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.